Human Anti-CSF1R Recombinant Antibody (clone RG7155) (CAT#: PABL-055)

Figure 1 Luminescence-based viability of M(IL-10), 6d differentiated under hypoxia (HPX) or normoxia (NMX) and inhibited for further 8d with 1 µg/mL RG7155 compared to IgG.

Pradel, L.P., Ooi, C.H., Romagnoli, S., et al. (2016). Macrophage susceptibility to emactuzumab (RG7155) treatment. Molecular Cancer Therapeutics, 15(12), 3077-3086.

Figure 2 Expression (log2-transformed RPKM) values of baseline and treated tumor biopsy samples from 31 patients enrolled in the Phase 1 Trial for CSF1-R and CD163.

Pradel, L.P., Ooi, C.H., Romagnoli, S., et al. (2016). Macrophage susceptibility to emactuzumab (RG7155) treatment. Molecular Cancer Therapeutics, 15(12), 3077-3086.

Figure 3 RG7155 inhibits monocyte survival during differentiation by TCM.

Monocytes were cultured for 6 days in TCM with 30 mg/ml RG7155 or huIgG, and survival was analyzed by DAPI staining. Columns depicted were normalized to viable cells in the corresponding huIgG control (at least three donors; mean ± SEM; pairwise t test; *p < 0.05, **p < 0.01). The corresponding M-CSF/GM-CSF ratio of TCM is indicated on the secondary scale (blue squares). TC-Macs were classified as GM-CSF/CSF-1 polarized and are depicted by black bars at a CSF-1/GM-CSF ratio <50.

Ries, C.H., Cannarile, M.A., Sabine Hoves, S., et al. (2014). Targeting Tumor-Associated Macrophages with Anti-CSF-1R Antibody Reveals a Strategy for Cancer Therapy. Cancer Cell, 25, 1-14.

Figure 4 Representative immunohistochemistry (IHC) images from one cynomolgus male animal is shown for each liver, colon, and lung from the vehicle-, 30 mg/kg RG7155-, and 100 mg/kg RG7155-treated groups (left).

Each group is represented by one male and one female treated once weekly for 2 weeks. Individual scores for the percent area coverage of the different cell types are shown for both animals per vehicle and dosing groups tested (right).

Ries, C.H., Cannarile, M.A., Sabine Hoves, S., et al. (2014). Targeting Tumor-Associated Macrophages with Anti-CSF-1R Antibody Reveals a Strategy for Cancer Therapy. Cancer Cell, 25, 1-14.